Complement Fragment 3a Proteins (C3a)

Complement component C3 plays a central role in the activation of complement system. Additionally we are shipping Complement Fragment 3a Kits (72) and Complement Fragment 3a Antibodies (8) and many more products for this protein.

list all proteins Gene Name GeneID UniProt
C3a 718 P01024
C3a    
C3a    
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top Complement Fragment 3a Proteins at antibodies-online.com

Showing 4 out of 7 products:

Catalog No. Origin Source Conjugate Images Quantity Supplier Delivery Price Details
Escherichia coli (E. coli) Human His tag,GST tag 100 μg Log in to see 15 to 18 Days
$672.00
Details
Escherichia coli (E. coli) Rat His tag 100 μg Log in to see 15 to 18 Days
$736.00
Details
Escherichia coli (E. coli) Pig His tag,GST tag 100 μg Log in to see 15 to 18 Days
$752.00
Details
Escherichia coli (E. coli) Mouse Un-conjugated SDS-PAGE analysis of Mouse C3a Protein. 100 μg Log in to see 11 to 18 Days
$710.67
Details

C3a Proteins by Origin and Source

Origin Expressed in Conjugate
Human

Mouse (Murine)
Rat (Rattus)

More Proteins for Complement Fragment 3a (C3a) Interaction Partners

Human Complement Fragment 3a (C3a) interaction partners

  1. The present study showed no association between methylation levels of C3 promoter and the risk of CAD. However, the methylation levels might be related to LDL-C levels.

  2. Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host major complement components C3, C4, and C5.

  3. The pooled ORs for rs551397, rs2274700, rs4151667, rs641153, rs1047286, rs9332739, and rs547154 in the heterozygote model were 0.53, 0.53 , 0.54, 0.48, 1.42, 0.50, and 0.52, respectively. We confirmed the protective role of C2/CFB/CFH polymorphisms in the development of Age-Related Macular Degeneration (AMD), and showed single nucleotide polymorphism in C3 was a high-risk factor for AMD

  4. Evasion of C3b deposition at division septa and lateral amplification underneath the capsule requires localization of the FH-binding protein PspC at division sites.

  5. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan.

  6. In our meta-analysis, C3 genetic polymorphisms unveiled a positive effect on the risk of advanced age-related macular degeneration, especially in Caucasians

  7. Case Report: recurrent proliferative glomerulonephritis with persistent isolated C3 deposition.

  8. A phage Ab against C3b that inhibited the alternative complement pathway, but not the classical pathway, was described in 2009. Studies using this Ab in a variety of assays have now demonstrated that it acts primarily by inhibiting tickover, thereby confirming that tickover really exists.

  9. Anti-HLA class I and class II C3d-binding donor-specific antibodies carried a twofold and 1.5-fold increased risk of kidney graft loss, respectively.

  10. Study shows no significant association of the C3 gene with uveitis, suggesting C3 confers either no or limited risk for uveitis susceptibility.

  11. Here we have shown for the first time, that ligand- or insulin-mediated activation of PPARgamma in human hepatoma cell line HepG2 causes the downregulation of C3 gene expression and protein secretion

  12. Single Nucleotide Polymorphism rs11569514 in C3 and haplotypes of C3 variants were associated with schizophrenia in a Han Chinese population.

  13. alphaXbeta2 uses the alphaX alphaI domain to bind iC3b on its C3c moiety at one of two sites.

  14. findings revealed a significant association between variant p.R102G in complement component C3 gene with exudative age-related macular degeneration in the Tunisian population

  15. SNPs within the complement genes may contribute to IA, the first step to type 1 diabetes, with at least one SNP in C3 significantly associated with clinically diagnosed type 1 diabetes.

  16. An increase in serum C4, as well as a decrease in C3, was an important outcome determinant for patients with immunoglobulin A nephropathy.

  17. rituximab was not effective in few cases of complement-mediated C3 glomerulonephritis and dense deposit disease . Despite promising results in immunoglobulin-associated and idiopathic Membranoproliferative glomerulonephritis, current evidence on this treatment remains weak, and controlled and prospective data are urgently needed.

  18. C3F polymorphism is associated with viral infections and protection from rejection after liver transplantation.

  19. Pra1 targets C3 by cleaving C3 at a unique site. This inhibited effector function of the activation fragments. The newly formed C3a-like peptide lacked the C-terminal arginine residue needed for C3a-receptor binding and activation. Pra1 also bound to C3a and C3b generated by human convertases and blocked their effector functions, C3a binding to human C3a receptor, C3 antifungal activity, and C3b deposition.

  20. data provide the first evidence that T17M rhodopsin mutant disrupts C3 secretion via the induction of ROS and the suppression of TWIST1.

Complement Fragment 3a (C3a) Protein Profile

Protein Summary

Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection.

Gene names and symbols associated with Complement Fragment 3a Proteins (C3a)

  • complement C3 (C3)
  • AHUS5 protein
  • ARMD9 protein
  • ASP protein
  • C3a protein
  • C3b protein
  • CPAMD1 protein

Protein level used designations for Complement Fragment 3a Proteins (C3a)

C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 , C3a anaphylatoxin , acylation-stimulating protein cleavage product , complement C3 , complement component C3 , complement component C3a , complement component C3b , prepro-C3

GENE ID SPECIES
718 Homo sapiens
Selected quality suppliers for Complement Fragment 3a Proteins (C3a)
Did you look for something else?